| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/17/2023 | 376.19% | HC Wainwright & Co. | → $17 | Reiterates | Buy → Buy |
| 08/04/2023 | 180.11% | Morgan Stanley | $10 → $10 | Reiterates | Equal-Weight → Equal-Weight |
| 08/04/2023 | 40.06% | Barclays | $7 → $5 | Maintains | Equal-Weight |
| 03/17/2023 | 376.19% | HC Wainwright & Co. | $15 → $17 | Maintains | Buy |
| 11/21/2022 | 68.07% | B of A Securities | → $6 | Downgrades | Neutral → Underperform |
| 11/17/2022 | 320.17% | HC Wainwright & Co. | $16 → $15 | Maintains | Buy |
| 11/15/2022 | 180.11% | Morgan Stanley | $11 → $10 | Maintains | Equal-Weight |
| 09/09/2022 | 208.12% | Morgan Stanley | $19 → $11 | Downgrades | Overweight → Equal-Weight |
| 07/29/2022 | 152.1% | Jefferies | → $9 | Initiates Coverage On | → Buy |
| 05/12/2022 | 348.18% | HC Wainwright & Co. | $62 → $16 | Maintains | Buy |
| 03/17/2022 | 432.21% | Morgan Stanley | $20 → $19 | Maintains | Overweight |
| 03/15/2022 | 180.11% | B of A Securities | $50 → $10 | Downgrades | Buy → Neutral |
| 02/28/2022 | 236.13% | Barclays | $20 → $12 | Downgrades | Overweight → Equal-Weight |
| 11/17/2021 | 460.22% | Barclays | $33 → $20 | Maintains | Overweight |
| 10/11/2021 | 880.39% | Morgan Stanley | $60 → $35 | Upgrades | Equal-Weight → Overweight |
| 10/08/2021 | 824.37% | Barclays | $80 → $33 | Maintains | Overweight |
| 07/27/2021 | 1580.67% | B of A Securities | → $60 | Upgrades | Neutral → Buy |
| 04/26/2021 | 1636.69% | HC Wainwright & Co. | → $62 | Initiates Coverage On | → Buy |
| 03/17/2021 | 1580.67% | Morgan Stanley | $47 → $60 | Maintains | Equal-Weight |
| 12/16/2020 | 1216.53% | Morgan Stanley | $38 → $47 | Maintains | Equal-Weight |
| 11/12/2020 | 964.43% | Morgan Stanley | $34 → $38 | Maintains | Equal-Weight |
| 10/20/2020 | 1020.45% | B of A Securities | → $40 | Initiates Coverage On | → Buy |
| 10/20/2020 | 936.41% | Goldman Sachs | → $37 | Initiates Coverage On | → Neutral |
| 10/20/2020 | — | Morgan Stanley | Initiates Coverage On | → Equal-Weight |
What is the target price for Prelude Therapeutics (PRLD)?
The latest price target for Prelude Therapeutics (NASDAQ: PRLD) was reported by HC Wainwright & Co. on August 17, 2023. The analyst firm set a price target for $17.00 expecting PRLD to rise to within 12 months (a possible 376.19% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Prelude Therapeutics (PRLD)?
The latest analyst rating for Prelude Therapeutics (NASDAQ: PRLD) was provided by HC Wainwright & Co., and Prelude Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Prelude Therapeutics (PRLD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prelude Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prelude Therapeutics was filed on August 17, 2023 so you should expect the next rating to be made available sometime around August 17, 2024.
Is the Analyst Rating Prelude Therapeutics (PRLD) correct?
While ratings are subjective and will change, the latest Prelude Therapeutics (PRLD) rating was a reiterated with a price target of $0.00 to $17.00. The current price Prelude Therapeutics (PRLD) is trading at is $3.57, which is within the analyst's predicted range.